Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

spondyloarthritis

- PMLiVE

J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis

The drug is the first IL-23 inhibitor approved for children from the age of six

- PMLiVE

Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies

The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population

- PMLiVE

Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

Approximately 125 million people globally are living with some form of psoriasis

- PMLiVE

Novartis and Matchpoint enter inflammatory disease partnership worth $1bn

The companies will focus on inflammatory diseases that have been historically difficult to treat

- PMLiVE

UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

Approximately 125 million people worldwide are affected by some form of psoriasis

- PMLiVE

J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis

Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

- PMLiVE

Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis

More than 2.5 million people in Europe are affected by the inflammatory bowel disease

- PMLiVE

Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

More than 2.5 million people in Europe are living with the inflammatory bowel disease

- PMLiVE

Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis

The inflammatory condition affects approximately 30% of psoriasis patients

- PMLiVE

Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease

Inflammatory bowel disease is estimated to affect nearly two million people across Europe

- PMLiVE

Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

An estimated three million people in the US are affected by inflammatory bowel disease

- PMLiVE

Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m

The common skin condition affects approximately 40 million people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links